Brooklyn ImmunoTherapeutics Announces Publication of Results of IRX-2 Monotherapy in Early Stage Breast Cancer in Breast Cancer Research
In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit.
- In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit.
- Providence Cancer Institute is home to the Earle A. Chiles Research Institute, a world-class research facility located within the Robert W. Franz Cancer Center in Portland, Oregon, and is a recognized leader in the field of cancer immunotherapy since 1993.
- These statements are based upon the current beliefs and expectations of Brooklyn\'s management and are subject to significant risks, uncertainties and other factors.
- Additional factors and risks are described in Brooklyn\xe2\x80\x99s periodic reports filed with the Securities and Exchange Commission, which are available on the SEC\'s website at www.sec.gov .